Vistagen Therapeutics, Inc.
VTGNBiotechnology
$0.17−1.41%As of Oct 30vs prior close
- Market cap
- $7.5M
- P/E (TTM)
- –
- From 52W high
- −96.57%
- EPS (LTM)
- -$1.66
- Revenue (LTM)
- $2.5M
- Net margin
- -2703.72%
- Dividend yield
- 0.00%
Nomior Score
20
Distressed LaggardBottom 7% of the scored universe
Growth57
Quality20
Value—
Momentum14
Resilience27
Growth
+0.17%revenue a year over 9 fiscal years
YE17 $1.3MLTM $2.5M
Connections
Revenue to profitQ1 YE27
The operating loss was 904% of revenue, narrower by 5573 pts on a year.
Who owns it
1fund